Andrew J. Murphy
CIK: 0001796226
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
REGENERON PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (39 total)
- Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct376 shares at avg. $775.46$292K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct50 shares at avg. $781.47$39K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct463 shares at avg. $780.63$361K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct380 shares at avg. $779.59$296K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct454 shares at avg. $778.64$354K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct38 shares at avg. $777.76$30K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct121 shares at avg. $774.48$94K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct66 shares at avg. $776.31$51K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct6 shares at avg. $753.76$5K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct35 shares at avg. $755.91$26K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct16 shares at avg. $757.68$12K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct24 shares at avg. $758.16$18K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct14 shares at avg. $759.96$11K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct74 shares at avg. $760.65$56K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct27 shares at avg. $761.36$21K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct55 shares at avg. $762.57$42K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct25 shares at avg. $763.76$19K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct219 shares at avg. $764.40$167K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct271 shares at avg. $765.39$207K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct279 shares at avg. $766.47$214K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct192 shares at avg. $767.39$147K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct105 shares at avg. $768.33$81K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct127 shares at avg. $769.30$98K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct12 shares at avg. $770.20$9K - Oct 14, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct283 shares at avg. $771.56$218K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 376 | $775.46 | $291,573 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 50 | $781.47 | $39,074 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 463 | $780.63 | $361,432 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 380 | $779.59 | $296,244 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 454 | $778.64 | $353,503 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 38 | $777.76 | $29,555 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 121 | $774.48 | $93,712 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 66 | $776.31 | $51,236 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 6 | $753.76 | $4,523 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 35 | $755.91 | $26,457 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 16 | $757.68 | $12,123 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 24 | $758.16 | $18,196 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 14 | $759.96 | $10,639 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 74 | $760.65 | $56,288 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 27 | $761.36 | $20,557 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 55 | $762.57 | $41,941 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 25 | $763.76 | $19,094 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 219 | $764.40 | $167,404 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 271 | $765.39 | $207,421 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 279 | $766.47 | $213,845 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 192 | $767.39 | $147,339 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 105 | $768.33 | $80,675 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 127 | $769.30 | $97,701 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 12 | $770.20 | $9,242 | Direct |
| Oct 14, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 283 | $771.56 | $218,351 | Direct |
1-25 of 39 transactions
About MURPHY ANDREW J
MURPHY ANDREW J (SEC CIK 0001796226) files insider reports with the SEC as Co-Chief Scientific Officer of REGENERON PHARMACEUTICALS, INC. (REGN).
Signal8 holds 7 ownership filings by MURPHY ANDREW J, all Form 4s, filed between Nov 12, 2024 and Oct 15, 2026. Those filings report 39 transactions, from Nov 8, 2024 to Oct 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on MURPHY ANDREW J's filings is in TARRYTOWN, NY.
Recent filings by MURPHY ANDREW J
- Oct 14, 2026: Open-market sales of REGN shares (25 lines, Form 4, code S).
Other insiders filing for REGENERON PHARMACEUTICALS, INC. (REGN)
- Guarini Kathryn, Director
- BROWN MICHAEL S, Director
- McCourt Marion, EVP Commercial
- LAROSA JOSEPH J, EVP General Counsel and Secret
- Fenimore Christopher R., EVP Finance CFO
- Zoghbi Huda Y, Director